Can Ganciclovir be Replaced with Valganciclovir as a Preemptive Therapy for Cytomegalovirus Infection in Hematopoietic Stem Cell Transplantu (HSCT) Recipients?

被引：0
|
作者：
Sachdev, M. [1 ]
Chakraborty, S. [1 ]
Bansal, M. [1 ]
Dua, V. [1 ]
机构：
[1] Fortis Mem Res Inst, Pediat Hematol Oncol Bmt, Gurugram, India
来源：
PEDIATRIC BLOOD & CANCER | 2021年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O0149
引用
收藏
页码：S73 / S74
页数：2
相关论文
共 50 条
  • [41] ORAL VALGANCICLOVIR IS EFFECTIVE AS PRE-EMPTIVE THERAPY FOR CYTOMEGALOVIRUS INFECTION IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS
    Atay, D.
    Erbey, F.
    Akcay, A.
    Dag, A.
    Ozturk, G.
    BONE MARROW TRANSPLANTATION, 2014, 49 : S460 - S460
  • [42] Randomized trial of preemptive valganciclovir therapy versus valacyclovir prophylaxis for the management of cytomegalovirus infection in kidney transplant recipients.
    Reischig, Tomas
    Jindra, Pavel
    Klaboch, Jan
    Svecova, Miroslava
    Hes, Ondrej
    Treska, Vladislav
    AMERICAN JOURNAL OF TRANSPLANTATION, 2007, 7 : 506 - 506
  • [43] WHICH IS THE OPTIMAL DOSAGE OF VALGANCICLOVIR AS PRE-EMPTIVE THERAPY FOR CYTOMEGALOVIRUS INFECTION IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT?
    Candoni, A.
    Simeone, E.
    Tiribelli, M.
    Fanin, R.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 67 - 67
  • [44] Phase 3 Randomized, double-blind Study of Maribavir Compared with Valganciclovir for Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic stem-cell Transplant (HSCT) Recipients (Study Design)
    Maertens, Johan
    Alain, Sophie
    Avery, Robin
    Murray, Rose Ann
    Wu, Jingyang
    Ljungman, Per
    BONE MARROW TRANSPLANTATION, 2020, 55 (SUPPL 1) : 500 - 500
  • [45] Comparison of universal prophylaxis and preemptive treatment with valganciclovir in management of cytomegalovirus infection in heart transplant recipients
    Vymetalova, Jevgenija
    Kubanek, Milos
    Gazdic, Tomas
    Vrbska, Jana
    Malek, Ivan
    Kautzner, Josef
    COR ET VASA, 2012, 54 (01) : E16 - E21
  • [46] Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients
    Khoury, J. A.
    Storcha, G. A.
    Bohl, D. L.
    Schuessler, R. M.
    Torrence, S. M.
    Lockwood, M.
    Gaudreault-Keener, M.
    Koch, M. J.
    Miller, B. W.
    Hardinger, K. L.
    Schnitzler, M. A.
    Brennan, D. C.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2006, 6 (09) : 2134 - 2143
  • [47] Pre-emptive therapy with valganciclovir for cytomegalovirus (CMV) infection after allogeneic haematopoietic stem cell transplantation (Allo-HSCT)
    Topcuoglu, P.
    Arslan, O.
    Ozcan, M.
    Ilhan, O.
    Akan, H.
    Uysal, A.
    Gurman, G.
    BONE MARROW TRANSPLANTATION, 2013, 48 : S322 - S323
  • [48] Cytomegalovirus Viral Load Threshold to Guide Preemptive Therapy in Hematopoietic Cell Transplant Recipients: Correlation With Cytomegalovirus Disease
    Sadowska-Klasa, Alicja
    Leisenring, Wendy M.
    Limaye, Ajit P.
    Boeckh, Michael
    JOURNAL OF INFECTIOUS DISEASES, 2024, 229 (05): : 1435 - 1439
  • [49] Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients
    Singh, N
    CLINICAL INFECTIOUS DISEASES, 2001, 32 (05) : 742 - 751
  • [50] LETERMOVIR COMBINED WITH GANCICLOVIR AS A PREEMPTIVE OR TREATMENT FOR CYTOMEGALOVIRUS INFECTION FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, A SINGLE-CENTER RETROSPECTIVE REVIEW
    Yao, Han
    Feng, Yimei
    Chen, Ting
    Zhao, Lu
    Liu, Yuqing
    Zhu, Lidan
    Liu, Jia
    Wang, Lu
    Gao, Shichun
    Liu, Huanfeng
    Gao, Lei
    Kong, Peiyan
    Zhang, Xi
    BONE MARROW TRANSPLANTATION, 2024, 59 : 468 - 469
12345